| HOME >> MEDICINE >> TECHNOLOGY |
28,696(1,018)161,145115,833Net earnings
162,160129,894642,934538,803Net earnings attributable to the noncontrolling interest
(196)(403)(2,084)(1,993)Net earnings attributable to Mylan Inc. common shareholders
$
,964$
29,491$
40,850$
536,810Earnings per common share attributable to Mylan Inc. common shareholders:Basic
$
.40$
.30$
.54$
.25Diluted
$
.39$
.30$
.52$
.22Weighted average common shares outstanding:Basic
406,840426,560415,210430,839Diluted
412,620429,691420,236438,785
Mylan Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited; in thousands)December 31,
2012December 31,
2011ASSETSAssetsCurrent assets:Cash and cash equivalents
$
349,969$
375,056Accounts receivable, net
1,554,3421,426,438Inventories
1,525,2421,396,742Other current assets
473,164370,608Total current assets
3,902,7173,568,844Intangible assets, net
2,224,4572,630,747Goodwill
3,515,6553,517,935Other non-current assets
2,289,0681,880,617Total assets
$
,931,897$
,598,143LIABILITIES AND EQUITYLiabilitiesCurrent liabilities (a)
$
2,193,503$
2,563,156Long-term debt
5,337,1964,479,080Other non-current liabilities
1,045,3701,051,125Total liabilities
8,576,0698,093,361Noncontrolling interest
15,11013,007Mylan Inc. shareholders' equity
3,340,7183,491,775Total liabilities and equity
$
,931,897$
,598,143(a) At December 31, 2011, long-term debt of approximately $594.0 million related to the Senior Convertible Notes was classified within current liabilities. In March 2012 the Senior Convertible Notes matured and were repaid.|
Mylan Inc. and Subsidiaries
Summary of Revenues by Segment
(Unaudited; in millions)Three Months EndedYear EndedThree
'/>"/>
| SOURCE Mylan Inc. Copyright©2012 PR Newswire. All rights reserved |